M Wiesenfeld
Overview
Explore the profile of M Wiesenfeld including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
174
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alberts S, Foster N, MORTON R, Kugler J, Schaefer P, Wiesenfeld M, et al.
Ann Oncol
. 2005 Aug;
16(10):1654-61.
PMID: 16085692
Background: PS-341 is a proteasome inhibitor with preclinical activity in pancreatic cancer tumor models and synergistic activity with gemcitabine. This randomized phase II study determined the tumor response rate (RR)...
2.
Alberts S, Townley P, Goldberg R, Cha S, Sargent D, Moore D, et al.
Ann Oncol
. 2003 Mar;
14(4):580-5.
PMID: 12649105
Background: This study was performed to determine the efficacy of gemcitabine and oxaliplatin in patients with advanced or metastatic pancreatic adenocarcinoma (ACA). Patients And Methods: Pancreatic ACA patients with previously...
3.
Alberts S, Townley P, Goldberg R, Cha S, Moore Jr D, Krook J, et al.
Ann Oncol
. 2002 Jun;
13(4):553-7.
PMID: 12056705
Background: The study was performed to determine the maximum tolerated dose (MTD) of gemcitabine and oxaliplatin in patients with advanced or metastatic pancreatic adenocarcinoma (ACA). Patients And Methods: Pancreatic ACA...
4.
Niedringhaus R, Hillman S, Geyer S, Sloan J, Krook J, Windschitl H, et al.
Am J Clin Oncol
. 2002 Jan;
24(6):551-5.
PMID: 11801752
Edatrexate is an antifolate agent with improved in vitro antineoplastic activity as compared with methotrexate. A Mayo phase I trial of edatrexate (E), vinblastine (V), doxorubicin (Adriamycin) (A), cisplatin (C),...
5.
Sloan J, Loprinzi C, Laurine J, Novotny P, Krook J, Oconnell M, et al.
J Clin Oncol
. 2001 Aug;
19(15):3539-46.
PMID: 11481361
Purpose: This article summarizes the third step of a research program to identify variables that supplement the predictive power of the the Eastern Cooperative Oncology Group (ECOG) performance status (PS)...
6.
Bonner J, Sloan J, Rowland Jr K, Klee G, Kugler J, Mailliard J, et al.
Clin Cancer Res
. 2000 Feb;
6(2):597-601.
PMID: 10690544
The level of serum neuron-specific enolase (NSE) has been implicated as a prognostic factor for patients with small cell lung cancer (SCLC). A prospective evaluation was undertaken to assess the...
7.
Goldberg R, Hatfield A, Kahn M, Sargent D, Knost J, Oconnell M, et al.
J Clin Oncol
. 1997 Nov;
15(11):3320-9.
PMID: 9363861
Purpose: A three-arm randomized phase III trial in advanced colorectal cancer patients was designed to test whether substitution of an equivalent dose of (1) l-leucovorin or (2) oral leucovorin would...
8.
Cascino T, Veeder M, Buckner J, OFallon J, Wiesenfeld M, Levitt R, et al.
J Neurooncol
. 1996 Dec;
30(3):243-6.
PMID: 8943099
Thirty patients with recurrent primary brain tumors were treated with a combination of 5-fluorouracil and leucovorin. There were three responses seen. Toxicity consisted of stomatitis, diarrhea, and hematological suppression. 5-fluorouracil...
9.
Wiesenfeld M, Oconnell M, Wieand H, Gonchoroff N, Donohue J, Fitzgibbons Jr R, et al.
J Clin Oncol
. 1995 Sep;
13(9):2324-9.
PMID: 7666090
Purpose: The primary goal of this study was to assess the effectiveness of interferon gamma (IFN-gamma) to prevent tumor relapse following potentially curative surgery in patients with high-risk colon cancer....
10.
Shaw E, Deming R, Creagan E, Nair S, Su J, Levitt R, et al.
Int J Radiat Oncol Biol Phys
. 1995 Feb;
31(4):827-31.
PMID: 7860395
Purpose: Gamma interferon has a wide range of properties, including the ability to sensitize solid tumor cells to the effects of ionizing radiation. The North Central Cancer Treatment Group has...